Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 07, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Acitretin Capsules USP, 10 mg, 17.5 mg, and 25 mg.".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 07, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Acitretin Capsules USP, 10 mg, 17.5 mg, and 25 mg.".